ABSTRACT
Purpose: Recommendations and guidelines consider cancer patients a high-priority population for COVID-19 immunization. Vaccination process in Serbia began in January 2021 with four available vaccines. We have conducted a cross-sectional study investigating cancer patients' acceptability of anti SARS-COV2 vaccines.
ABSTRACT
Purpose: Recommendations and guidelines consider cancer patients a high-priority population for COVID-19 immuni zation. Vaccination process in Serbia began in January 2021 with four available vaccines. We have conducted a cross-sectional study investigating cancer patients' acceptability of anti SARS-COV2 vaccines. Methods: The study included 767 patients with solid and hematologic malignancies treated at the Oncology Institute of Vojvodina, Serbia. During July and August 2021 patients filled in an individual paper questionnaire on anti SARS-COV2 vaccination acceptance, preferences, side effects and information origin. Data on treatment phase, diagnosis and treatment was collected from electronic health records. Results: During the first six months of vaccination cam-paign in Serbia 41% (320/767) of the investigated oncol ogy patients received COVID-19 vaccines. The median age of vaccinated patients was 65 years (28-84). Most of them (75%) were in active treatment of cancer. Half of the un vaccinated patients (52%) wish to get vaccinated after the end of their cancer treatment. Around 10% of the patients definitely refused vaccination. The majority of information on COVID-19 vaccines cancer patients got from their oncolo gist, television and newspapers. Side effects were reported by 10.93% of the patients after the first dose and 13.31% after the second dose. No serious side effects were reported. Conclusion: We have confirmed that patients are reluctant of receiving vaccine due to fear of side effects, especially dur ing the active cancer treatment. However, real-world evidence and clinical trials data have gathered enough evidence to reassure any doubts of the patients and their oncologists on safety and efficacy of anti SARS-COV2 vaccines. © 2021 Zerbinis Publications. All rights reserved.